EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants

Jun Morita iD, Hiroki Sato, Masayo Sumiya, Risako Takaya, Kazuya Ishiwata, Shogo Matsumoto, Takuma Yonemura, Yuji Kumagai

Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)

DOI: 10.1128/aac.00282-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Jun Morita und 7 weiteren Autor:innen. Beteiligte Einrichtung: R&D Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meiji Seika Pharma Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted an open-label study to assess the pharmacokinetics, safety, and tolerability of nacubactam—a β-lactamase inhibitor—administered alone or in combination with β-lactam antibiotic. Japanese healthy male participants received a single dose of nacubactam 2 g on Day 1, a single dose of β-lactam antibiotic (cefepime 2 g, aztreonam 2 g, meropenem 2 g, and piperacillin 4 g in Cohorts 1, 2, 3, and 4, respectively) on Day 3, and the combination of nacubactam and β-lactam antibiotic on Day 5. The study drugs were intravenously administered over 60 min. A total of 32 participants (8 in each cohort) were enrolled in the study. All participants completed the study and were included in the analysis. Exposures to nacubactam or β-lactam antibiotic (maximum plasma concentration [ C max ], area under the plasma concentration-time curve from time zero to the last quantifiable time [AUC 0−t ], and AUC from time zero to infinity [AUC 0−∞ ]) were similar between the treatment periods (monotherapy vs combination therapy) in all cohorts. Coadministration of nacubactam and β-lactam antibiotic did not affect the pharmacokinetic profile of nacubactam or β-lactam antibiotic with the 90% confidence intervals for the geometric least squares mean ratios (combination therapy/monotherapy) of C max , AUC 0−t , and AUC 0−∞ contained within the equivalence range of 0.80 to 1.25 for all study drugs. Nacubactam and β-lactam antibiotics were well tolerated. All treatment emergent adverse events were mild in severity and resolved without treatment. Our results support the further clinical development of nacubactam coadministered with these β-lactam antibiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase InhibitorsAdultHumansMaleMiddle AgedYoung AdultArea Under Curvebeta Lactam Antibioticsbeta-LactamsCefepimeDrug InteractionsHealthy VolunteersJapanMeropenemPiperacillinThienamycinsEast Asian PeopleLactams

Stichwörter der Autor:innen

aztreonambeta-lactamase inhibitorclinical trial, phase 1meropenemnacubactampharmacokineticspiperacillinsafety cefepime

Substanzen

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta Lactam Antibioticsbeta-Lactamase Inhibitorsbeta-LactamsCefepimeMeropenemnacubactamPiperacillin

Autor:innen und Institutionen

  • R&D Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
  • Souseikai Sumida Hospital, Tokyo, Japan.
  • Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

ORCID-Profile: Jun Morita

Förderung

  • Meiji Seika Pharma Co., Ltd.

Zitieren

APA

Morita, J., Sato, H., Sumiya, M., Takaya, R., Ishiwata, K., Matsumoto, S., Yonemura, T., & Kumagai, Y. (2026). Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.00282-26

Vancouver

Morita J, Sato H, Sumiya M, Takaya R, Ishiwata K, Matsumoto S, et al. Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.00282-26

BibTeX
@article{Morita2026,
  author = {Morita, Jun and Sato, Hiroki and Sumiya, Masayo and Takaya, Risako and Ishiwata, Kazuya and Matsumoto, Shogo and Yonemura, Takuma and Kumagai, Yuji},
  title = {Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {7},
  doi = {10.1128/aac.00282-26}
}
Kostenlos starten →